Kexing Biopharm's latest marketcap:
As of 07/26/2025, Kexing Biopharm's market capitalization has reached $1.34 B. According to our data, Kexing Biopharm is the 8237th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 1.34 B |
| Revenue (ttm) | 195.27 M |
| Net Income (ttm) | 6.23 M |
| Shares Out | 199.38 M |
| EPS (ttm) | 0.03 |
| Forward PE | 87.76 |
| Ex-Dividend Date | 06/12/2025 |
| Earnings Date | 08/23/2025 |
Kexing Biopharm's yearly market capitalization.
| Date | Market Cap(¥) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 07/26/2025 | ¥9.62 B | $1.34 B | 132.35% | 8237 |
| 12/31/2024 | ¥4.32 B | $592.04 M | 7.17% | 11884 |
| 12/29/2023 | ¥4.03 B | $568.12 M | -5.31% | 12164 |
| 12/30/2022 | ¥4.26 B | $617.29 M | -24.16% | 10927 |
| 12/31/2021 | ¥5.62 B | $883.99 M | -30.78% | 10003 |
| 12/31/2020 | ¥8.11 B | $1.24 B | 7012 |
Company Profile
About Kexing Biopharm Co., Ltd.
Kexing Biopharm Co., Ltd. is a biopharmaceutical company specializing in the research, development, production, and sale of recombinant protein drugs and microbial preparations. Operating in China and internationally, the company focuses on innovative therapies across multiple therapeutic areas.
Key Therapeutic Focus Areas
- Antiviral
- Tumor and Immunity
- Blood Disorders
- Digestive Diseases
- Degenerative Diseases
Product Portfolio
Recombinant Protein Drugs:
- Recombinant human interferon α1b
- Human erythropoietin
- Human granulocyte stimulating factor
Other Key Products:
- Clostridium butyricum combined live bacteria powder
- Kehuang Capsule (Chinese patent medicine)
- Entecavir (chemical drug)
- Liraglutide (human glucagon-like peptide-1)
- Albumin-Paclitaxel, Infliximab, Bevacizumab
- Adalimumab, Trastuzumab
- Neratinib maleate tablets
- Lenalidomide capsules
Company Background: Founded in 1989 and headquartered in Jinan, China, Kexing Biopharm has established itself as a key player in the biopharmaceutical industry.
Frequently Asked Questions
-
What is Kexing Biopharm's (SHA-688136) current market cap?As of 07/26/2025, Kexing Biopharm (including the parent company, if applicable) has an estimated market capitalization of $1.34 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Kexing Biopharm (SHA-688136) rank globally by market cap?Kexing Biopharm global market capitalization ranking is approximately 8237 as of 07/26/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.